As previously reported, on 16 May 2017 Minister of Health Jane Philpott announced a consultation regarding proposed amendments to the Patented Medicines Regulations that would significantly affect the Patented Medicines Prices Review Board’s (PMPRB’s) approach to drug price evaluation.
Key proposed changes include:
- new factors in determining whether the price of a drug is excessive
- expanding the list of comparator countries used to determine whether a price is excessive, but excluding the United States and Switzerland
- requiring the disclosure of all indirect price reductions, such as rebates and discounts
The consultation closed on 28 June 2017, and the proposed regulatory amendments are expected to published in Autumn this year.
The vice chair of the PMPRB issued a statement welcoming the actions to “strengthen and modernise [the PMPRB’s] pricing framework to reduce the cost of prescription drugs”.